title: [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
abstract: OBJECTIVE
  This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension.
  
  
  METHODS
  We randomly divided 360 LUTS patients with concomitant hypertension into a 5 mg amlodipine group, a 2 mg terazosin group and a 5 mg amlodipine plus 2 mg terazosin group, and measured PVR at the baseline and 4 weeks after the treatment.
  
  
  RESULTS
  For male patients with LUTS associate with hypertension, all of amlodipine (APVR = 6.8) , terazosin (APVR = 7. 6), and combination group (APVR = 8.8) can significant reduced the PVR (P < . 0.1), but no significant difference was found among three groups.
  
  
  CONCLUSIONS
  Amlodipine alone or combined with terazosin can improve the PVR of the LUTS patient effectively, but had no significant difference compared with terazosin.
authors.affiliation: Anhui Provincial Institute of Biomedicine, Anhui Medical University, Hefei, Anhui 230032, China.
authors.forename: Chun
authors.initials: C
authors.lastname: Yang
authors.forename: You-Long
authors.initials: YL
authors.lastname: Li
authors.forename: Jian
authors.initials: J
authors.lastname: Fang
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhang
authors.forename: Hai-Peng
authors.initials: HP
authors.lastname: Liu
authors.forename: Xian-Hui
authors.initials: XH
authors.lastname: Qin
authors.forename: Xi-Ping
authors.initials: XP
authors.lastname: Xu
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D016055:Urinary Retention / Q000150:complications / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D017311:Amlodipine; C041226:Terazosin; D011224:Prazosin